Lyell Immunopharma, Inc. Annual Operating Income (Loss) in USD from 2019 to 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Lyell Immunopharma, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2019 to 2023.
  • Lyell Immunopharma, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$50.5M, a 14.5% increase year-over-year.
  • Lyell Immunopharma, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$217M, a 7.33% decline year-over-year.
  • Lyell Immunopharma, Inc. annual Operating Income (Loss) for 2023 was -$247M, a 32% decline from 2022.
  • Lyell Immunopharma, Inc. annual Operating Income (Loss) for 2022 was -$187M, a 12.9% increase from 2021.
  • Lyell Immunopharma, Inc. annual Operating Income (Loss) for 2021 was -$215M, a 1.34% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$247M -$60M -32% Jan 1, 2023 Dec 31, 2023 10-K 2024-02-28
2022 -$187M +$27.7M +12.9% Jan 1, 2022 Dec 31, 2022 10-K 2024-02-28
2021 -$215M -$2.84M -1.34% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-28
2020 -$212M -$110M -108% Jan 1, 2020 Dec 31, 2020 10-K 2023-02-28
2019 -$102M Jan 1, 2019 Dec 31, 2019 10-K 2022-03-29
* An asterisk sign (*) next to the value indicates that the value is likely invalid.